Zacks.com on MSN3h
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...
Yahoo Finance4h
Pfizer drug for hemophilia approved by FDA
Recommended Reading Pfizer says hemophilia drug succeeded in Phase 3 study The Food and Drug Administration on Friday ...
Pharmaceutical Technology7h
FDA approves Pfizer’s HYMPAVZI to treat haemophilia
Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...
Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
pharmaphorum10h
Pfizer rounds out haemophilia portfolio with FDA approval
The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...
Pharmabiz3h
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...
Daily7h
Pfizer Hemophilia drug Hympavzi Receives USFDA Approval
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
The Financial Express10h
USFDA gives nod to Pfizer’s drug therapy for patients with Hemophilia
The FDA granted the approval of Hympavzi to Pfizer Inc.
Medscape2d
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ ...
Managed Healthcare Executive2d
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...